Surya Pharma strengthens global footprint

Surya Pharmaceutical Limited,one of the leading Pharma companies in the country has achieved a yet another milestone with European Directorate for the Quality of Medicines (EDQM) awarding the Certificate of Suitability (COS) for its key product ‘Cefalexin Monohydrate’.

Written by Charanjit Ahuja | Chandigarh | Published: April 20, 2012 12:15 pm

Chandigarh based Surya Pharmaceutical Limited,one of the leading Pharma companies in the country has achieved a yet another milestone with European Directorate for the Quality of Medicines (EDQM) awarding the Certificate of Suitability (COS) for its key product ‘Cefalexin Monohydrate’.

Mutual Funds Check for top funds

The Cefalexin Monohydrate is a first generation cephalosporin antibiotic used especially in the treatment of respiratory and urinary tract infections. This is the second product being awarded with COS,the first one being Cefixime,earlier awarded by EDQM with COS.

Stocks More on Surya Pharmaceuticals Ltd.

Surya Pharma is a strong global player fulfilling requirements of its clients in over 90 countries. Headed by Rajiv Goyal,Chairman and Managing Director,the Surya group also has business interests in healthcare,education,infrastructure and communications. Considered as one of the largest manufacturers and exporters of mint and menthol derivatives,the company also manages the-state-of-the- art research and development centres.

Company INFO More on Surya Pharmaceuticals Ltd.

The company has its network of overseas offices in China,Singapore and USA and has set up a Research and Development Centre at San Diego,USA to further strengthen its position as one of the leading exporters of pharmaceutical products.

This prestigious certification is expected to not only leverage Surya in better sales realizations but also allow the company to tap highly remunerative regulated markets like Europe,Middle East,Brazil,Mexico,Taiwan etc. Showcasing the industry’s best manufacturing capabilities with the Company,this accomplishment will also build a stronger sense of confidence amongst the domestic as well as international clients.

Company officials claimed here today that ”with an intent to widen its product portfolio in the diverse world markets,Surya expects more such approvals for its other products like Cefuroxime Axetil and Cefaclor very shortly”. Continuing the momentum,Surya has also been approved by Teva,the world’s largest generic drugs manufacturer,for the supply of some key intermediates which will give further impetus to the Company’s international presence.

For all the latest News Archive News, download Indian Express App

    Live Cricket Scores & Results